Slicing the Pie: Entity Formation and the Division of Equity

qed@qb3 - UCB Friday, March 5, 2010 12:00 to 1:00 pm Stanley Hall Room 621

Matt Kirmayer will lead a discussion of the issues relating to forming an entity, seeding it with the assets and IP to be successful, and avoiding the potential pitfalls  when dividing up the equity among the founders.

Matt Kirmayer is a member in the Corporate practice. His practice is focused on the representation of emerging technology companies, venture capital and private equity funds and institutional investors.  Matt represents clients in many industries, such as multimedia, wireless technologies, networking, internet infrastructure and security, nanotechnology, life sciences and medical devices. He also represents NY Money Center Banks and institutional investors in capital market transactions. Prior to joining Mintz Levin, Matt was a partner at a San Francisco area law firm. Matt began his career in New York City handling securities offerings and merger and acquisition transactions. Matt is admitted to practice law in California and New York.  He received a J.D. from Rutgers University and an LL.M. from New York University School of Law.

Lunch provided, but space is limited so please reserve a seat here.

http://qb3.org/services/qed-qb3/?searchterm=qed

...But what do I know? Lessons learned from living through a couple of spin-out companies

qed@qb3 UCSF Thursday, March 4, 2010 12:00 to 1:00 pm Byers Hall Room 212

There are many lessons to be learned in the formation of spinouts. Tom will walk through his experiences going from an academic setting to a spinout company and what he has learned from this and a couple of other companies that he has been close to (Avantome, TrueMaterials, Boreal Genomics)

Tom Willis is the CEO of MLC Dx Inc. a VC backed company dedicated to the commercialization of molecular diagnostic tests. Prior to founding MLC, Tom has been an entrepreneur in the biotech industry for the past decade. After receiving his Ph.D. in physics from Stanford University, he joined the Stanford Genome Technology Center (SGTC) to work on DNA sequence analysis technologies. He held several positions at the SGTC including Associate Director in charge of technology development. While at SGTC, he co-invented the Molecular Inversion Probe technology for high throughput genotyping. In 2001, he co-founded ParAllele BioScience to develop and commercialize this technology. As its founding CEO, he led ParAllele through two rounds of VC financing a grew the company to over 80 employees. In 2005 ParAllele was acquired by Affymetrix at which time Tom served in several management positions at Affymetrix. He left in 2007 to pursue new startup opportunities. In addition to his role at MLC, Tom serves on the boards of SpinX Technologies and Boreal Genomics

Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=198455

http://qb3.org/services/qed-qb3/?searchterm=qed